$PHAT

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Its approved products are VOQUEZNA tablets, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, all containing vonoprazan, an oral potassium-competitive acid blocker. VOQUEZNA is approved for certain erosive and non-erosive GERD symptoms and, with antibiotics, for H. pylori infection; the two co-packaged PAK products are approved for H. pylori infection. Phathom began U.S. commercialization in November 2023 and sells its products exclusively in the United States. Phathom makes money through sales of its three products, which it sells primarily to pharmaceutical wholesale distributors and select pharmacies. It independently commercializes the products through a targeted U.S. sales force and works with third-party pharmacy support providers. The company is headquartered in Florham Park, New Jersey.

AlphAI earnings readthird quarter 2026 · OCT 29Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdateVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
3
1

No SEC Form 4 filings for $PHAT in the last 30 days.

See all $PHAT insider activity →
Low

Phathom Pharmaceuticals' Robert Breedlove to Resign as Finance VP

Phathom Pharmaceuticals' VP of Finance, Robert Breedlove, will resign on December 4, 2026, according to an SEC filing. The company stated his departure is not due to any disagreement with its operations or policies. No replacement has been announced.

Phathom Pharmaceuticals, Inc. (PHAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 12, 2026, Robert Breedlove, Vice President, Finance and principal accounting officer, of Phathom Pharmaceuticals

PHAT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning PHAT (Phathom Pharmaceuticals, Inc.). Coverage has skewed bearish: 0 bullish, 3 neutral, and 1 bearish.

Recent PHAT coverage spans earnings, financial news and corporate actions.

What's driving PHAT

AlphAI scores every news story that mentions PHAT with an AI model for sentiment and relevance, and aggregates insider trades from Phathom Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PHAT

Score
$PHATLowExec change· resigned

Phathom Pharmaceuticals, Inc. (PHAT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 12, 2026, Robert Breedlove, Vice President, Finance and principal accounting officer, of Phathom Pharmaceuticals

Phathom Pharmaceuticals (PHAT) Offers Eligible Patients VOQUEZNA for as Little as $0

Phathom Pharmaceuticals (PHAT) announced that eligible patients may pay as little as $0 for VOQUEZNA tablets through BlinkRx, with free home delivery and prior authorization support. The program is subject to eligibility requirements and benefit limits. Cash-pay options start at $55 per 30-day supply, with state-specific discounts in Massachusetts. No financial impact or revenue estimates were provided.

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMedAI 8/10Earnings

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G

Phathom Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration’s establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit…

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 26, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the U.S. Food and Drug Administration’s (“FDA’s”) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions

Related tickers